Jump to main content
Jump to site search


Repositioning Salirasib as a new antimalarial agent

Author affiliations

Abstract

Malaria is a serious tropical disease that kills thousands of people every year, mainly in Africa, due to Plasmodium falciparum infections. Salirasib is a promising cancer drug candidate that interferes with the post-translational modification of Ras. This S-farnesyl thiosalicylate inhibits isoprenylcysteine carboxyl methyltransferase (ICMT), a validated target for cancer drug development. There is a high homology between the human and the parasite enzyme isoforms, in addition to being a druggable target. Looking to repurpose its structure as an antimalarial drug, a collection of S-substituted derivatives of thiosalicylic acid were prepared by introducing 1,2,3-triazole as a diversity entry point or by direct alkylation of the thiol. We further investigated the in vitro toxicity of FTS analogues to Plasmodium falciparum in the asexual stages and in Vero cells. An antiplasmodial activity assay was performed using a simple, high-sensitivity methodology based on nanoluciferase (NLuc)-transfected P. falciparum parasites. The results showed that some of the analogs were active at low micromolar concentration, including Salirasib. The most potent member of the series has S-farnesyl and the 1,2,3-triazole moiety substituted with phytyl. However, the compound substituted with methyl-naphthyl shows promising physicochemical and activity values. The low cytotoxicity in eukaryotic cells of the most active analogs provided good therapeutic indices, being starting-point candidates for future antimalarial drug development.

Graphical abstract: Repositioning Salirasib as a new antimalarial agent

Back to tab navigation

Supplementary files

Publication details

The article was received on 29 May 2019, accepted on 18 Jun 2019 and first published on 21 Jun 2019


Article type: Research Article
DOI: 10.1039/C9MD00298G
Med. Chem. Commun., 2019, Advance Article

  •   Request permissions

    Repositioning Salirasib as a new antimalarial agent

    E. O. J. Porta, I. Bofill Verdaguer, C. Perez, C. Banchio, M. Ferreira de Azevedo, A. M. Katzin and G. R. Labadie, Med. Chem. Commun., 2019, Advance Article , DOI: 10.1039/C9MD00298G

Search articles by author

Spotlight

Advertisements